TriSalus Life Sciences Prelim. Q4 Revenue Surges

(RTTNews) - TriSalus Life Sciences, Inc. (TLSI), Thursday announced 44 percent increase in preliminary fourth-quarter revenue to around $8.3 million, than the last year.

The company noted that the revenue growth was driven solely by the TriNav Infusion System, an innovative solution designed to overcome infusion barriers within solid tumors.

Meanwhile, TriSalus anticipates revenue of about $29.4 million for the fiscal year 2024, representing a year-over-year increase of nearly 59 percent.

The medical technology company further expects the revenue growth to rise by over 50 percent in the full year 2025, which is in consistence with the previously estimated outlook.

Currently, TriSalus's stock is climbing 2.04 percent, to $5 on the Nasdaq.